$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-Q Financial Statement

#000078516112000066 Filed on October 26, 2012

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q4
Revenue	$552.9M	$537.0M	$518.1M
YoY Change	6.72%	7.9%	5.54%
Cost Of Revenue	$26.20M	$23.80M	$26.10M
YoY Change	0.38%	-3.64%	0.0%
Gross Profit	$519.5M	$506.2M	$485.9M
YoY Change	6.92%	8.19%	4.54%
Gross Profit Margin	93.96%	94.26%	93.78%
Selling, General & Admin	$315.0M	$307.5M	$298.2M
YoY Change	5.63%	6.81%	5.48%
% of Gross Profit	60.64%	60.75%	61.37%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$21.70M	$21.30M	$20.20M
YoY Change	7.43%	9.23%	4.12%
% of Gross Profit	4.18%	4.21%	4.16%
Operating Expenses	$414.7M	$404.2M	$390.1M
YoY Change	6.31%	7.02%	4.25%
Operating Profit	$104.8M	$102.0M	$95.80M
YoY Change	9.39%	13.08%	5.74%
Interest Expense	-$21.30M	-$20.20M	-$19.90M
YoY Change	7.04%	-12.93%	-37.62%
% of Operating Profit	-20.32%	-19.8%	-20.77%
Other Income/Expense, Net	$1.100M	$6.100M	$1.200M
YoY Change	-8.33%	2950.0%	-20.0%
Pretax Income	$81.90M	$88.50M	$82.70M
YoY Change	-0.97%	71.18%	75.58%
Income Tax	$24.50M	$28.10M	$15.20M
% Of Pretax Income	29.91%	31.75%	18.38%
Net Earnings	$47.00M	$47.10M	$50.00M
YoY Change	-6.0%	-17.37%	-93.58%
Net Earnings / Revenue	8.5%	8.77%	9.65%
Basic Earnings Per Share	$0.43	$0.43	$0.45
Diluted Earnings Per Share	$0.43	$0.43	$0.46
COMMON SHARES
Basic Shares Outstanding	95.66M shares	94.70M shares
Diluted Shares Outstanding		108.1M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$132.8M	$163.2M	$30.10M
YoY Change	341.2%	242.14%	-54.74%
Cash & Equivalents	$132.8M	$163.2M	$30.10M
Short-Term Investments
Other Short-Term Assets	$117.2M	$138.1M	$138.1M
YoY Change	-15.13%	-3.76%	3.83%
Inventory
Prepaid Expenses
Receivables	$249.3M	$247.5M	$222.8M
Other Receivables	$18.00M	$0.00	$11.70M
Total Short-Term Assets	$636.8M	$548.8M	$491.6M
YoY Change	29.54%	33.72%	21.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$748.0M	$739.3M	$664.4M
YoY Change	12.58%	13.95%	4.98%
Goodwill	$437.3M	$437.3M	$421.7M
YoY Change	3.7%		0.33%
Intangibles	$73.20M	$73.60M	$57.70M
YoY Change	26.86%		-1.37%
Long-Term Investments	$19.20M		$27.10M
YoY Change	-29.15%		-3.56%
Other Assets	$135.4M	$130.7M	$128.3M
YoY Change	5.53%	-82.54%	-11.03%
Total Long-Term Assets	$1.787B	$1.907B	$1.780B
YoY Change	0.44%	2.52%	-9.48%
TOTAL ASSETS
Total Short-Term Assets	$636.8M	$548.8M	$491.6M
Total Long-Term Assets	$1.787B	$1.907B	$1.780B
Total Assets	$2.424B	$2.456B	$2.271B
YoY Change	6.74%	8.15%	-4.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.30M	$51.90M	$45.40M
YoY Change	-0.22%	14.32%	1.79%
Accrued Expenses	$111.6M	$325.9M	$107.5M
YoY Change	3.81%	34.28%	9.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$13.60M		-$18.90M
YoY Change	-171.96%		30.34%
Total Short-Term Liabilities	$300.9M	$377.8M	$313.2M
YoY Change	-3.93%	31.14%	-12.83%
LONG-TERM LIABILITIES
Long-Term Debt	$1.240B	$1.242B	$1.236B
YoY Change	0.33%	-5.07%	-17.44%
Other Long-Term Liabilities	$24.00M	$137.9M	$30.40M
YoY Change	-21.05%	2.15%	7.42%
Total Long-Term Liabilities	$24.00M	$137.9M	$1.266B
YoY Change	-98.1%	-90.45%	-16.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$300.9M	$377.8M	$313.2M
Total Long-Term Liabilities	$24.00M	$137.9M	$1.266B
Total Liabilities	$1.671B	$1.758B	$1.682B
YoY Change	-0.65%	-3.18%	-15.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.425B		-$2.610B
YoY Change	-7.09%		-7.4%
Common Stock	$1.000M		$1.000M
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$163.3M		$148.8M
YoY Change	9.74%		4.94%
Treasury Stock Shares	5.234M shares		4.489M shares
Shareholders Equity	$291.0M	$244.7M	$117.0M
YoY Change
Total Liabilities & Shareholders Equity	$2.424B	$2.456B	$2.271B
YoY Change	6.74%	8.15%	-4.25%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q4
OPERATING ACTIVITIES
Net Income	$47.00M	$47.10M	$50.00M
YoY Change	-6.0%	-17.37%	-93.58%
Depreciation, Depletion And Amortization	$21.70M	$21.30M	$20.20M
YoY Change	7.43%	9.23%	4.12%
Cash From Operating Activities	$109.3M	$107.2M	$129.4M
YoY Change	-15.53%	94.2%	93.42%
INVESTING ACTIVITIES
Capital Expenditures	-$31.50M	-$33.80M	-$47.20M
YoY Change	-33.26%	28.03%	130.24%
Acquisitions		$1.000M
YoY Change
Other Investing Activities	-$23.00M	-$2.200M	-$10.10M
YoY Change	127.72%	-102.03%	-30.82%
Cash From Investing Activities	-$54.50M	-$36.00M	-$57.30M
YoY Change	-4.89%	-143.96%	63.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-85.20M	50.90M	-89.70M
YoY Change	-5.02%	-134.02%	-48.42%
NET CHANGE
Cash From Operating Activities	109.3M	107.2M	129.4M
Cash From Investing Activities	-54.50M	-36.00M	-57.30M
Cash From Financing Activities	-85.20M	50.90M	-89.70M
Net Change In Cash	-30.40M	122.1M	-17.60M
YoY Change	72.73%	-1076.8%	-87.61%
FREE CASH FLOW
Cash From Operating Activities	$109.3M	$107.2M	$129.4M
Capital Expenditures	-$31.50M	-$33.80M	-$47.20M
Free Cash Flow	$140.8M	$141.0M	$176.6M
YoY Change	-20.27%	72.79%	102.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1800000	shares
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-700000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	7700000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1500000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	45400000	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	51900000	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	222800000	USD
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	247500000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18100000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14400000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	74900000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	128200000	USD
CY2012Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	26700000	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	21400000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3300000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2700000	USD
CY2012Q3	us-gaap	Assets Assets	2456200000	USD
CY2011Q4	us-gaap	Assets Assets	2271200000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	391000000	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	548800000	USD
CY2012Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	75000000	USD
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	75900000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	-6000000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	-15700000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30100000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163200000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48300000	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	133100000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	9400000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	56300000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	140100000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	48200000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	158400000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12800000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	38600000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33400000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	7900000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	4900000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	11300000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	191800000	USD
CY2011Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	67600000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	178700000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	61000000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	426100000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1277100000	USD
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	405200000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1208900000	USD
CY2012Q3	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	1321900000	USD
CY2011Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	1254700000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	80400000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23400000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	553100000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	26600000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	526500000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	608100000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49100000	USD
CY2012Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21300000	USD
CY2011Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	58600000	USD
CY2011Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6500000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	19500000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	18100000	USD
CY2012Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5700000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	18100000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	19500000	USD
CY2012Q3	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2011Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2012Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2011Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.49
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.44
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	9700000	USD
CY2012Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	4900000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	7100000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	19600000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	21500000	USD
CY2011Q3	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	7000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	21500000	USD
CY2011Q3	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	7000000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	7100000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	19600000	USD
CY2012Q3	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	18600000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	64000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	64200000	USD
CY2011Q3	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	22400000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000000	USD
CY2012Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1600000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3900000	USD
CY2011Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2800000	USD
CY2011Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12700000	USD
CY2012Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1300000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1300000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-38800000	USD
CY2012Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2700000	USD
CY2011Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26400000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	80700000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29300000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	87300000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	421700000	USD
CY2012Q3	us-gaap	Goodwill Goodwill	437300000	USD
	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	15600000	USD
CY2012Q3	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	15600000	USD
CY2012Q3	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	11100000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1609000000	USD
CY2011Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	497700000	USD
CY2012Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	537000000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1508800000	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	5900000	USD
CY2011Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	4600000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	103800000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	135400000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	47600000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	22200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	32700000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	11400000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	12800000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	34500000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	38600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	160200000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	51700000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	88500000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	258100000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	174000000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	138300000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	60400000	USD
CY2011Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	33600000	USD
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	1.23
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.44
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.17
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.90
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	53800000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-500000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	2600000	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	34700000	USD
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-500000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	2600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	54900000	USD
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	34800000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.59
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.03
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.37
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9700000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8800000	USD
CY2012Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3300000	USD
CY2011Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3100000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21900000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84100000	USD
CY2011Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18100000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1400000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42300000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27400000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	13100000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10200000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5800000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-6300000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-7600000	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	13100000	shares
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	12200000	shares
CY2011Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	13100000	shares
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	57700000	USD
CY2012Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73600000	USD
CY2011Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	26300000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	69800000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	96300000	USD
CY2012Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	23500000	USD
CY2012Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	20900000	USD
CY2011Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	29000000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	730600000	USD
CY2011Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	245000000	USD
CY2012Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	262300000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	780700000	USD
CY2012Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	41400000	USD
CY2012Q3	us-gaap	Liabilities Liabilities	1758000000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	1682200000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2271200000	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2456200000	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	377800000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	313200000	USD
CY2011Q4	us-gaap	Line Of Credit LineOfCredit	110000000	USD
CY2012Q3	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2012Q3	us-gaap	Loans Payable To Bank LoansPayableToBank	0	USD
CY2011Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	97500000	USD
CY2012Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1242300000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1235800000	USD
CY2012Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	79600000	USD
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	18900000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All lawsuits purporting to be derivative complaints filed in the Circuit Court of Jefferson County, Alabama since 2002 have been consolidated and stayed in favor of the first-filed action captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy</font><font style="font-family:inherit;font-size:10pt;"> and filed August 28, 2002. Derivative lawsuits in other jurisdictions have been stayed. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> complaint asserted claims on our behalf against, among others, a number of our former officers and directors and Ernst & Young LLP, our former auditor. When originally filed, the primary allegations in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case involved self-dealing by Richard M. Scrushy, our former chairman and chief executive officer, and other insiders through transactions with various entities allegedly controlled by Mr. Scrushy. The complaint was amended four times to add additional defendants and include claims of accounting fraud, improper Medicare billing practices, and additional self-dealing transactions. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation, including a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> judgment against Mr. Scrushy, and the related settlements to date are more fully described in “Litigation Against Richard M. Scrushy” and “Litigation By and Against Former Independent Auditor” below and in Note 21, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlements</font><font style="font-family:inherit;font-size:10pt;">, “UBS Litigation Settlement,” and Note 22, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2011 Form 10-K.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation Against Richard M. Scrushy— </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 18, 2009, the Circuit Court of Jefferson County, Alabama ruled in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case on our derivative claims against Mr. Scrushy presented during a nonjury trial held May 11 to May 26, 2009. The court held Mr. Scrushy responsible for fraud and breach of fiduciary duties and awarded us </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> in damages. On July 24, 2009, Mr. Scrushy filed a notice of appeal of the trial court’s decision, and the parties subsequently submitted their briefs to the Supreme Court of Alabama. On January 28, 2011, the Supreme Court upheld the trial court’s decision in its entirety. On April 15, 2011, the Alabama Supreme Court denied Mr. Scrushy's application for a rehearing of its initial decision. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pursue collection aggressively and to the fullest extent permitted by law. We, in coordination with derivative plaintiffs' counsel, are attempting to locate, in order to collect the judgment, Mr. Scrushy's current assets and other assets we believe were improperly disposed. Part of this effort is a fraudulent transfer complaint filed on July 2, 2009 against Mr. Scrushy and a number of related entities by derivative plaintiffs for the benefit of HealthSouth in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy et al</font><font style="font-family:inherit;font-size:10pt;">. While these collection efforts continue, some of Mr. Scrushy’s assets have been seized and sold at auction pursuant to the state law procedure for collection of a judgment. Other assets will likewise be sold from time to time. On May 3, 2011, the Circuit Court of Jefferson County entered an order for distribution of amounts collected and liquidated. After reimbursement of reasonable out-of-pocket expenses incurred by HealthSouth and the attorneys for the derivative shareholder plaintiffs for property maintenance of and fees incurred to locate Mr. Scrushy's assets and after recording a liability for the federal plaintiffs' </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25%</font><font style="font-family:inherit;font-size:10pt;"> apportionment of any net recovery from Mr. Scrushy as required in our consolidated securities action settlement, we recorded a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> net gain in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government, class action, and related settlements</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations for the year ended December 31, 2011 in connection with our receipt of cash distributions. During the three and nine months ended September 30, 2012, we recorded a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> net gain in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government, class action, and related settlements</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations in connection with our receipt of additional cash distributions.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For further discussion of our consolidated securities action settlement that previously resolved claims brought against us by former stockholders and bondholders, see Note 21, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Settlements</font><font style="font-family:inherit;font-size:10pt;">, "Securities Litigation Settlement" to the consolidated financial statements accompanying the 2011 Form 10-K. We are obligated to pay </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">35%</font><font style="font-family:inherit;font-size:10pt;"> of any recovery from Mr. Scrushy along with reasonable out-of-pocket expenses to the attorneys for the derivative shareholder plaintiffs. In connection with those obligations, during 2011, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> of the amounts previously collected were distributed to attorneys for the derivative shareholder plaintiffs. During the three and nine months ended September 30, 2012, an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the amounts collected were distributed to attorneys for the derivative shareholder plaintiffs. We recorded these cash distributions as part of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional fees—accounting, tax, and legal</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated statements of operations for the year ended December 31, 2011 and the three and nine months ended September 30, 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Former Independent Auditor—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2003, claims on behalf of HealthSouth were brought in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation against Ernst & Young, alleging that from 1996 through 2002, when Ernst & Young served as our independent auditor, Ernst & Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst & Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further allege Ernst & Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims seek compensatory and punitive damages, disgorgement of fees received from us by Ernst & Young, and attorneys’ fees and costs. On March 18, 2005, Ernst & Young filed a lawsuit captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ernst & Young LLP v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> in the Circuit Court of Jefferson County, Alabama. The complaint alleges we provided Ernst & Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst & Young claims that as a result of our actions, Ernst & Young’s reputation has been injured and it has and will incur damages, expenses, and legal fees. On April 1, 2005, we answered Ernst & Young’s claims and asserted counterclaims related or identical to those asserted in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> action. Upon Ernst & Young’s motion, the Alabama state court referred Ernst & Young’s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth and Ernst & Young. On July 12, 2006, we and the derivative plaintiffs filed an arbitration demand on behalf of HealthSouth against Ernst & Young. On August 7, 2006, Ernst & Young filed an answering statement and counterclaim in the arbitration reasserting the claims made in state court. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst & Young in arbitration.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are vigorously pursuing our claims against Ernst & Young and defending the claims against us. The three-person arbitration panel that is adjudicating the claims and counterclaims in arbitration was selected under rules of the American Arbitration Association (the "AAA"). The trial phase of the arbitration process began on July 12, 2010 and is currently stayed. We requested that the panel review and consider the ongoing proceedings in another case, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re State of Alabama Department of Revenue v. HealthSouth Corporation, et al.,</font><font style="font-family:inherit;font-size:10pt;"> which the Supreme Court of Alabama agreed on August 17, 2012 to hear on appeal. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re Alabama</font><font style="font-family:inherit;font-size:10pt;"> case is itself unrelated to the Ernst & Young arbitration but does involve an issue of Alabama law that is in dispute in the arbitration. The issue is whether, under Alabama law, the wrongdoing of disloyal employees can or should be imputed to the employer. The Supreme Court is scheduled to hear oral arguments on November 7, 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">However, pursuant to an order of the AAA panel, all aspects of the arbitration are confidential. Accordingly, we will not discuss the details of the arbitration until there is a resolution. Based on the stage of arbitration, and review of the current facts and circumstances, we do not believe there is a reasonable possibility of a loss that might result from an adverse judgment or a settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2004, General Medicine, P.C. filed a lawsuit against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine's underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine's complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;">, plus interest from the date of the judgment until paid at the rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum (the “Consent Judgment”). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS's parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS's creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have denied liability to General Medicine and asserted counterclaims against General Medicine for fraud, injurious falsehood, tortious interference with business relations, conspiracy, unjust enrichment, abuse of process, and other causes of action. In our counterclaims, we alleged the Consent Judgment is the product of fraud, collusion and bad faith by General Medicine and Meadowbrook and, further, that these parties were guilty of a conspiracy to manufacture a lawsuit against HealthSouth in favor of General Medicine. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, after we obtained discovery concerning the circumstances that lead to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, a three-judge panel of the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. On June 26, 2012, the Sixth Circuit Court of Appeals denied our application for rehearing by the full court. Due to the conclusion of the appeal in the Michigan Action, General Medicine requested reactivation of the Alabama Action in the Circuit Court of Jefferson County, Alabama. On October 4, 2012, the Alabama Action was assigned to a judge in the commercial litigation docket. An initial status conference has been set for November 9, 2012.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. We intend to vigorously defend ourselves against General Medicine's claims and to vigorously prosecute our counterclaims against General Medicine.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs' counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers removed the case to federal court on September 14, 2012. We filed a motion to remand the case back to state court on October 12, 2012. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were named as a defendant in a lawsuit filed March 3, 2009 by an individual in the Court of Common Pleas, Richland County, South Carolina, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sulton v. HealthSouth Corp, et al.</font><font style="font-family:inherit;font-size:10pt;"> The plaintiff alleged that certain treatment he received at a HealthSouth facility complicated a pre-existing infectious injury. The plaintiff sought recovery for pain and suffering, medical expenses, punitive damages, and other damages. On July 30, 2010, the jury in this case returned a verdict in favor of the plaintiff for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in damages. On May 29, 2012, the Supreme Court of South Carolina granted the parties' joint motion to submit the appeal directly to that court. The parties have completed their briefing for the appeal, and the Supreme Court heard oral arguments on October 17, 2012. We believe the attending nurses acted both responsibly and professionally, and we will continue to support and defend them. Although we continue to believe in the merit of our defenses and counterarguments, we have recorded a liability of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses and other current liabilities</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheets as of September 30, 2012 and December 31, 2011 with a corresponding receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</font><font style="font-family:inherit;font-size:10pt;"> for the portion of the claim we expect to be covered through our excess insurance coverages, resulting in a net charge of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other operating expenses</font><font style="font-family:inherit;font-size:10pt;"> in our consolidated statement of operations for the year ended December 31, 2010. The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> portion of this claim would be a covered claim through our captive insurance subsidiary, HCS, Ltd. As a result of the verdict, we made a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment through HCS, Ltd. to the Richland County Clerk as a deposit during the on-going appeal process. The deposit is a restricted asset included in O</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ther current assets</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheets as of September 30, 2012 and December 31, 2011.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that we are unaware of such filings or have been ordered by the presiding court not to discuss or disclose the filing of such lawsuits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital ("LTCH") we closed in August 2011, from the Dallas, Texas office of the HHS-OIG. The subpoena is in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requests documents and materials relating to this closed LTCH's patient admissions, length of stay, and discharge matters. We are cooperating fully with the HHS-OIG in connection with this subpoena and are currently unable to predict the timing or outcome of this investigation. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also face certain financial risks and challenges relating to our 2007 divestiture transactions (see Note 18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets and Liabilities in and Results of Discontinued Operations</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2011 Form 10-K) following their closing. These include indemnification obligations or other claims and assessments, which in the aggregate could have a material adverse effect on our financial position, results of operations, and cash flows.</font></div></div>
CY2011Q3	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2012Q3	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	84600000	USD
CY2012Q3	us-gaap	Minority Interest MinorityInterest	111300000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	34200000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	29500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-44800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-246600000	USD
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.017
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2100000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	0	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124300000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	213200000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	302200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	158700000	USD
	us-gaap	Net Income Loss NetIncomeLoss	138000000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	47100000	USD
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	57000000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	38600000	USD
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	12800000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33400000	USD
CY2011Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	11300000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	50500000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	139200000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	41400000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	119100000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	13900000	USD
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	138100000	USD
CY2012Q3	us-gaap	Other Assets Current OtherAssetsCurrent	138100000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128300000	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130700000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1100000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-700000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-300000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-500000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2100000	USD
CY2011Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-700000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	200000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1100000	USD
CY2012Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	75400000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	222800000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	216600000	USD
CY2011Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	70300000	USD
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	267800000	USD
CY2012Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	325900000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	133200000	USD
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	137900000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2300000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3800000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6100000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7400000	USD
CY2011Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	200000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1500000	USD
CY2012Q3	us-gaap	Other Notes Payable OtherNotesPayable	37300000	USD
CY2011Q4	us-gaap	Other Notes Payable OtherNotesPayable	35300000	USD
	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	11400000	USD
	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	10900000	USD
	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2800000	USD
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	46000000	USD
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4300000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7000000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	37600000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	34000000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	18900000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	19500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55900000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	8600000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	8000000	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	USD
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	9500000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	107900000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	100000000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	120000000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	275000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	135000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	338000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	4300000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	400000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Profit Loss ProfitLoss	192100000	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	59900000	USD
CY2011Q3	us-gaap	Profit Loss ProfitLoss	68300000	USD
	us-gaap	Profit Loss ProfitLoss	176600000	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	739300000	USD
	hls	Government Class Action And Related Settlements Cf GovernmentClassActionAndRelatedSettlementsCf	2600000	USD
	hls	Government Class Action And Related Settlements Cf GovernmentClassActionAndRelatedSettlementsCf	6500000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	664400000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14900000	USD
CY2011Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5100000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	19800000	USD
CY2012Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7000000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	10100000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8900000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	101300000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	503000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	238000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	245000000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	us-gaap	Share Based Compensation ShareBasedCompensation	18100000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14400000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	200000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4400000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	117000000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	244700000	USD
CY2012Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356000000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	201600000	USD
CY2011Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151800000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2200000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-3500000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-3300000	USD
	us-gaap	Supplies Expense SuppliesExpense	76700000	USD
	us-gaap	Supplies Expense SuppliesExpense	76200000	USD
CY2012Q3	us-gaap	Supplies Expense SuppliesExpense	23800000	USD
CY2011Q3	us-gaap	Supplies Expense SuppliesExpense	24700000	USD
CY2011Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	387400000	USD
CY2012Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	342200000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6000000	USD
CY2012Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79000000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	-700000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	100000	USD
CY2012Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	74100000	USD
	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	-400000	USD
CY2012Q3	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	1000000	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15900000	shares
CY2012Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13400000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13600000	shares
CY2011Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15900000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109100000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108200000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109200000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108100000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93300000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93200000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94600000	shares
CY2012Q3	hls	Available Cash Amounts Used For Debt Reduction AvailableCashAmountsUsedForDebtReduction	1900000	USD
CY2011Q3	hls	Cash And Cash Equivalents Of Facilities In Discontinued Operations Ending Balance CashAndCashEquivalentsOfFacilitiesInDiscontinuedOperationsEndingBalance	0	USD
CY2012Q3	hls	Cash And Cash Equivalents Of Facilities In Discontinued Operations Ending Balance CashAndCashEquivalentsOfFacilitiesInDiscontinuedOperationsEndingBalance	0	USD
CY2011Q3	hls	Cash And Cash Equivalents Of Facilities In Discontinuted Operations Beginning Balance CashAndCashEquivalentsOfFacilitiesInDiscontinutedOperationsBeginningBalance	100000	USD
CY2012Q3	hls	Cash And Cash Equivalents Of Facilities In Discontinuted Operations Beginning Balance CashAndCashEquivalentsOfFacilitiesInDiscontinutedOperationsBeginningBalance	0	USD
	hls	Cash Provided By Used In Other Investing Activities Of Discontinued Operations CashProvidedByUsedInOtherInvestingActivitiesOfDiscontinuedOperations	7700000	USD
	hls	Cash Provided By Used In Other Investing Activities Of Discontinued Operations CashProvidedByUsedInOtherInvestingActivitiesOfDiscontinuedOperations	-700000	USD
CY2011Q3	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2012Q3	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2011Q3	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-13300000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-39100000	USD
CY2012Q3	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-9600000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-37500000	USD
	hls	Estimated Effective Blended Federal And State Income Tax Rate EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate	0.40
	hls	Estimated Effective Blended Federal And State Income Tax Rate EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate	0.39
CY2011Q3	hls	Estimated Effective Blended Federal And State Income Tax Rate EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate	0.40
CY2012Q3	hls	Estimated Effective Blended Federal And State Income Tax Rate EstimatedEffectiveBlendedFederalAndStateIncomeTaxRate	0.390
	hls	Estimated Income Tax Expense Associated With Federal Income Tax On State Income Tax Refunds Received EstimatedIncomeTaxExpenseAssociatedWithFederalIncomeTaxOnStateIncomeTaxRefundsReceived	4000000	USD
CY2011Q3	hls	Estimated Income Tax Expense Associated With Federal Income Tax On State Income Tax Refunds Received EstimatedIncomeTaxExpenseAssociatedWithFederalIncomeTaxOnStateIncomeTaxRefundsReceived	4000000	USD
CY2012Q3	hls	Excess Tax Benefits From Share Based Compensation ExcessTaxBenefitsFromShareBasedCompensation	8300000	USD
	hls	Increase Decrease In Refunds Due Patients And Other Third Party Payors IncreaseDecreaseInRefundsDuePatientsAndOtherThirdPartyPayors	-15800000	USD
CY2012Q3	hls	Initial Suspension Period Medicare Payments InitialSuspensionPeriodMedicarePayments	180	D
CY2012Q3	hls	Letter Of Credit Subfacility Maximum Borrowing Capacity LetterOfCreditSubfacilityMaximumBorrowingCapacity	260000000	USD
	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-10600000	USD
CY2011Q3	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	0	USD
	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-3500000	USD
CY2012Q3	hls	Government Class Action And Related Settlements Expense GovernmentClassActionAndRelatedSettlementsExpense	-3500000	USD
CY2012Q3	hls	Guarantees Maximum Term GuaranteesMaximumTerm	54	M
CY2012Q3	hls	Guarantees Minimum Term GuaranteesMinimumTerm	1	M
CY2012Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	41900000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	116500000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	84300000	USD
CY2011Q3	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	15700000	USD
CY2011Q3	hls	Income Tax Benefit Resulting From Reduction In Unrecognized Tax Benefits IncomeTaxBenefitResultingFromReductionInUnrecognizedTaxBenefits	-2000000	USD
	hls	Income Tax Benefit Resulting From Reduction In Unrecognized Tax Benefits IncomeTaxBenefitResultingFromReductionInUnrecognizedTaxBenefits	-8000000	USD
	hls	Income Tax Benefit Resulting From Tax Settlement IncomeTaxBenefitResultingFromTaxSettlement	-24000000	USD
CY2012Q3	hls	Income Tax Expense Resulting From Application Of Blended Federal And State Rate IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate	30000000	USD
	hls	Income Tax Expense Resulting From Application Of Blended Federal And State Rate IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate	50000000	USD
CY2011Q3	hls	Income Tax Expense Resulting From Application Of Blended Federal And State Rate IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate	16000000	USD
	hls	Income Tax Expense Resulting From Application Of Blended Federal And State Rate IncomeTaxExpenseResultingFromApplicationOfBlendedFederalAndStateRate	86000000	USD
	hls	Increase Decrease In Refunds Due Patients And Other Third Party Payors IncreaseDecreaseInRefundsDuePatientsAndOtherThirdPartyPayors	3300000	USD
CY2012Q3	hls	Medicare Denials Percentage Collected After Appeal MedicareDenialsPercentageCollectedAfterAppeal	0.58
CY2012Q3	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	530000000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1589200000	USD
CY2011Q3	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	492600000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1493900000	USD
CY2012Q3	hls	Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures	9	facilities
CY2012Q3	hls	Number Of Guarantees NumberOfGuarantees	11
CY2012Q3	hls	Number Of Partially Owned Subsidiaries Nonconsolidated NumberOfPartiallyOwnedSubsidiariesNonconsolidated	13	facilities
	hls	Occupancy Cost OccupancyCost	36600000	USD
CY2011Q3	hls	Occupancy Cost OccupancyCost	12500000	USD
CY2012Q3	hls	Occupancy Cost OccupancyCost	11800000	USD
	hls	Occupancy Cost OccupancyCost	36200000	USD
	hls	Ownership Percentage Of Subsidiary Guarantors OwnershipPercentageOfSubsidiaryGuarantors	1.00
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.194
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.198
CY2012Q3	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.191
CY2011Q3	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.200
CY2011Q3	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.016
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.013
CY2012Q3	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.014
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.017
CY2011Q3	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.720
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.731
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.718
CY2012Q3	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.731
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.015
CY2011Q3	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
CY2012Q3	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.015
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.018
CY2012Q3	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.020
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.020
CY2011Q3	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.019
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.018
CY2011Q3	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.013
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.014
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.012
CY2012Q3	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.014
CY2011Q3	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2012Q3	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2011Q3	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.016
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.015
CY2012Q3	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.015
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	26900000	USD
	hls	Premium Received On Bond Issuance PremiumReceivedOnBondIssuance	4100000	USD
	hls	Premium Received On Bond Issuance PremiumReceivedOnBondIssuance	0	USD
CY2012Q3	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	4100000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	13200000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	16200000	USD
CY2011Q3	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	4000000	USD
	hls	Provision For Government Class Action And Related Settlements Expense ProvisionForGovernmentClassActionAndRelatedSettlementsExpense	-3500000	USD
	hls	Provision For Government Class Action And Related Settlements Expense ProvisionForGovernmentClassActionAndRelatedSettlementsExpense	-10600000	USD
CY2012Q3	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
CY2011Q3	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	800000	USD
	hls	Repurchase Of Convertible Perpetual Preferred Stock RepurchaseOfConvertiblePerpetualPreferredStock	0	USD
CY2012Q4	hls	Senior Notes Issuance Proceeds Used For Debt Reduction SeniorNotesIssuanceProceedsUsedForDebtReduction	64500000	USD
CY2012Q4	hls	Senior Notes Redemption Price Expressed As Percentage Of Principal SeniorNotesRedemptionPriceExpressedAsPercentageOfPrincipal	1.03
CY2012Q2	hls	Share Based Compensation Equity Instruments Other Than Options Issued In Period ShareBasedCompensationEquityInstrumentsOtherThanOptionsIssuedInPeriod	200000	shares
CY2012Q1	hls	Share Based Compensation Equity Instruments Other Than Options Issued In Period ShareBasedCompensationEquityInstrumentsOtherThanOptionsIssuedInPeriod	900000	shares
	hls	Share Based Compensation Equity Instruments Other Than Options Service Requirement Only Issued In Period ShareBasedCompensationEquityInstrumentsOtherThanOptionsServiceRequirementOnlyIssuedInPeriod	600000	shares
	hls	Treasury Stock Reacquired TreasuryStockReacquired	11900000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	4300000	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions	0	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedReductionsResultingFromLapseOfApplicableStatuteOfLimitations	-100000	USD
CY2012Q3	hls	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations And Settlements With Taxing Authorities UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitationsAndSettlementsWithTaxingAuthorities	1000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Period End Date DocumentPeriodEndDate	2012-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2012Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95661996	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2011Q2	dei	Entity Public Float EntityPublicFloat	2500000000	USD
	dei	Entity Registrant Name EntityRegistrantName	HEALTHSOUTH CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes

Files In Submission

Name	View Source	Status
0000785161-12-000066-index-headers.html	Edgar Link	pending
0000785161-12-000066-index.html	Edgar Link	pending
0000785161-12-000066.txt	Edgar Link	pending
0000785161-12-000066-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
hls-20120930.xml	Edgar Link	completed
hls-20120930.xsd	Edgar Link	pending
hls-20120930_cal.xml	Edgar Link	unprocessable
hls-20120930_def.xml	Edgar Link	unprocessable
hls-20120930_lab.xml	Edgar Link	unprocessable
hls-20120930_pre.xml	Edgar Link	unprocessable
hls10q93012.htm	Edgar Link	pending
hls10q93012ex101.htm	Edgar Link	pending
hls10q93012ex311.htm	Edgar Link	pending
hls10q93012ex312.htm	Edgar Link	pending
hls10q93012ex321.htm	Edgar Link	pending
hls10q93012ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2012 Q4 Form 10-Q Financial Statement

#000078516112000066 Filed on October 26, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2012 Q4 Form 10-Q Financial Statement

#000078516112000066 Filed on October 26, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc